TN2011000319A1 - Substituted quinazoline compounds - Google Patents

Substituted quinazoline compounds

Info

Publication number
TN2011000319A1
TN2011000319A1 TN2011000319A TN2011000319A TN2011000319A1 TN 2011000319 A1 TN2011000319 A1 TN 2011000319A1 TN 2011000319 A TN2011000319 A TN 2011000319A TN 2011000319 A TN2011000319 A TN 2011000319A TN 2011000319 A1 TN2011000319 A1 TN 2011000319A1
Authority
TN
Tunisia
Prior art keywords
methods
kinase
diseases
ameliorating
treating
Prior art date
Application number
TN2011000319A
Other languages
English (en)
French (fr)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000319(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of TN2011000319A1 publication Critical patent/TN2011000319A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TN2011000319A 2008-12-29 2011-06-27 Substituted quinazoline compounds TN2011000319A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (en) 2008-12-29 2009-12-18 Substituted quinazoline compounds

Publications (1)

Publication Number Publication Date
TN2011000319A1 true TN2011000319A1 (en) 2012-12-17

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000319A TN2011000319A1 (en) 2008-12-29 2011-06-27 Substituted quinazoline compounds

Country Status (23)

Country Link
US (1) US8389530B2 (https=)
EP (1) EP2381943A1 (https=)
JP (1) JP2012514020A (https=)
KR (1) KR20110120878A (https=)
CN (1) CN102333533A (https=)
AU (1) AU2009334869A1 (https=)
BR (1) BRPI0924067A2 (https=)
CA (1) CA2748319A1 (https=)
CO (1) CO6390105A2 (https=)
CR (1) CR20110368A (https=)
DO (1) DOP2011000209A (https=)
EA (1) EA019110B1 (https=)
EC (1) ECSP11011204A (https=)
IL (1) IL213742A0 (https=)
MA (1) MA32968B1 (https=)
MX (1) MX2011007064A (https=)
NI (1) NI201100134A (https=)
NZ (1) NZ593949A (https=)
PE (1) PE20120424A1 (https=)
SG (1) SG172415A1 (https=)
TN (1) TN2011000319A1 (https=)
WO (1) WO2010076238A1 (https=)
ZA (1) ZA201104777B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386955A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6-二取代的喹唑啉、喹喔啉、喹啉和异喹啉
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20060247250A1 (en) 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
JP5079500B2 (ja) * 2005-04-28 2012-11-21 協和発酵キリン株式会社 2−アミノキナゾリン誘導体
NZ563984A (en) 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition

Also Published As

Publication number Publication date
NZ593949A (en) 2013-08-30
ZA201104777B (en) 2012-03-28
US20120004210A1 (en) 2012-01-05
BRPI0924067A2 (pt) 2016-01-26
CA2748319A1 (en) 2010-07-08
AU2009334869A2 (en) 2011-09-29
IL213742A0 (en) 2011-07-31
SG172415A1 (en) 2011-07-28
EA019110B1 (ru) 2014-01-30
CO6390105A2 (es) 2012-02-29
WO2010076238A1 (en) 2010-07-08
JP2012514020A (ja) 2012-06-21
MX2011007064A (es) 2012-01-20
CR20110368A (es) 2011-12-02
AU2009334869A1 (en) 2011-07-14
PE20120424A1 (es) 2012-05-04
ECSP11011204A (es) 2011-10-31
EA201101012A1 (ru) 2012-01-30
US8389530B2 (en) 2013-03-05
MA32968B1 (fr) 2012-01-02
DOP2011000209A (es) 2011-09-30
KR20110120878A (ko) 2011-11-04
CN102333533A (zh) 2012-01-25
NI201100134A (es) 2012-03-06
EP2381943A1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
TN2011000319A1 (en) Substituted quinazoline compounds
TN2011000379A1 (en) [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
SG194718A1 (en) Novel compounds as modulators of protein kinases
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
IN2012DN02469A (https=)
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2009011850A3 (en) Novel therapeutic compounds
AU2016219704A1 (en) Anti-Notch1 antibodies
HK1199643A1 (en) Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009003724A (es) Derivados de 2-aminocarbonil-piridina.
IN2012DN02471A (https=)
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2012125408A8 (en) Pegylated apelin and uses thereof
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MX2013015347A (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2010126609A3 (en) Treatment of diseases with altered smooth muscle contractility
MX2013006118A (es) Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.